You are here
Internationonal Tumour Board - Case-Based Discussion of Real-World Clinical Management of Patients with Progressive Metastatic Colorectal Cancer (R)
Fri 25 Sept / 17:00 - 19:00 / Hall A4
The multi-kinase inhibitor regorafenib is approved for treatment of patients with mCRC who were previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy. In this symposium, experts share their real-world clinical experiences, using a case-based format, to guide appropriate patient selection and illustrate the clinical benefit of treatment with regorafenib. Proactive adverse event management strategies for patients receiving regorafenib treatment are also provided (G.MKT.SM.ON.10.2015.1417).
Welcome / Review of Clinical Trial Experience and Perspective on Optimal Patient Selection for Regorafenib in mCRC
R.D. Hofheinz (Germany)
R.D. Hofheinz introduces the Symposium, exploring the evolution of the current treatment paradigm for mCRC and discussing appropriate patient selection for the integration of regorafenib into the treatment paradigm for pretreated mCRC.
A. Grothey (USA)
Axel Grothey talks about his personal, practical experience of having used regorafenib since the onset of the CORRECT study, in the context of working at the Mayo Clinic Rochester, providing a framework of the experiences.
T. Yoshino (Japan)
T. Yoshino gives the Japanese perspective, especially for the management of the hand-foot skin reaction and liver enzyme elevation. The presentation covers relevant clinical trials and care standards.
G. Prager (Austria)
Gerald Prager provides the context of the use of regorafenib in daily clinical life with the ESMO guidelines. The presentation includes case studies from Europe and considers alternatives to standard treatments.